Next Article in Journal
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Next Article in Special Issue
Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines
Previous Article in Journal / Special Issue
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy

Gas Vesicle Nanoparticles for Antigen Display

Department of Microbiology and Immunology, Institute of Marine and Environmental Technology, University of Maryland, Baltimore, MD 21202, USA
Author to whom correspondence should be addressed.
Academic Editor: Darrell J. Irvine
Vaccines 2015, 3(3), 686-702;
Received: 26 June 2015 / Revised: 17 August 2015 / Accepted: 31 August 2015 / Published: 7 September 2015
(This article belongs to the Special Issue Nanoparticle-Based Vaccines)
Microorganisms like the halophilic archaeon Halobacterium sp. NRC-1 produce gas-filled buoyant organelles, which are easily purified as protein nanoparticles (called gas vesicles or GVNPs). GVNPs are non-toxic, exceptionally stable, bioengineerable, and self-adjuvanting. A large gene cluster encoding more than a dozen proteins has been implicated in their biogenesis. One protein, GvpC, found on the exterior surface of the nanoparticles, can accommodate insertions near the C-terminal region and results in GVNPs displaying the inserted sequences on the surface of the nanoparticles. Here, we review the current state of knowledge on GVNP structure and biogenesis as well as available studies on immunogenicity of pathogenic viral, bacterial, and eukaryotic proteins and peptides displayed on the nanoparticles. Recent improvements in genetic tools for bioengineering of GVNPs are discussed, along with future opportunities and challenges for development of vaccines and other applications. View Full-Text
Keywords: protein nanoparticle; adjuvant; carrier; SIV; Chlamydia; Salmonella; typhoid; Plasmodium; malaria; luciferase protein nanoparticle; adjuvant; carrier; SIV; Chlamydia; Salmonella; typhoid; Plasmodium; malaria; luciferase
Show Figures

Figure 1

MDPI and ACS Style

DasSarma, S.; DasSarma, P. Gas Vesicle Nanoparticles for Antigen Display. Vaccines 2015, 3, 686-702.

AMA Style

DasSarma S, DasSarma P. Gas Vesicle Nanoparticles for Antigen Display. Vaccines. 2015; 3(3):686-702.

Chicago/Turabian Style

DasSarma, Shiladitya, and Priya DasSarma. 2015. "Gas Vesicle Nanoparticles for Antigen Display" Vaccines 3, no. 3: 686-702.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop